JAMP Pharma Group is active in all sectors of the pharmaceutical industry with our JAMP Pharma generic products, our BioJAMP biosimilar products, our Orimed Pharma branded products, our Wampole and Laboratoire Suisse natural health products, and our Cosmetic Import beauty and personal care products.
For more than 35 years, we have been committed to supporting healthcare professionals so that they may focus on what matters most: the well-being of Canadians. We have made healthcare solutions more accessible and affordable for both patients and consumers.
As we look to the future, we are committed to ensuring that our diversified product portfolio remains accessible to all, while guaranteeing the most reliable supply in Canada.
Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)
PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, ICELAND & BOUCHERVILLE, QC (November 9, 2023) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP…
BIOJAMP, New launches, News and events, Press release
Discover the one of a kind ready-to-drink gels electrifying the Canadian market!
Wampole and Laboratoire Suisse are making waves with the launch of two new energy products: Swical Energy Shot and Ultra Energy Shot. These ready-to-drink energy gels are redefining the energy market with their innovative formula combining vitamins and plant extracts. With only 20 calories per serving, no caffeine, and zero…
Laboratoire Suisse, New launches, News and events, Wampole
JAMP Pharma Group receives Health Canada approval for Pr JAMP Dapagliflozin, a new generic alternative for the treatment of type 2 diabetes
The JAMP Pharma Group has received authorization to market Dapagliflozin, offering a more affordable alternative to the reference product Forxiga® (marketed by AstraZeneca Canada Inc.). The JAMP Pharma Group, a leader in product launches1, is expending its product line for the treatment of diabetes, bringing it closer to achieving its goal…
New launches, Press release